Cost-Effective HIV PrEP: CAB-LA Transforms Prev...

By Rene Pretorius

April 16, 2025

Summary Cabotegravir long-acting (CAB-LA) delivers a cost-effective HIV PrEP solution. It reduces infections and supports the Ending the HIV Epidemic (EHE) initiative. This review exami...
Neoadjuvant Immunotherapy Efficacy: Enhancing Treatment Strategies for Head a...
Enhancing UK Clinical Trials Inclusivity: Opportunities and Innovations in Me...
Cost-Effective Interventions for HIV, Malaria, Syphilis, and TB in 128 Countries
Challenges in Accelerating Innovative Paediatric Medicine
Balancing Pandemic Preparedness Priorities and Military Spending
Exploring the MASLD CKD Socioeconomic Link
Toripalimab Evidence Journey in Cancer Care
Approval of Pembrolizumab Enfortumab Therapy: Insights on Efficacy, Costs, an...
Cancer Control Month 2025: Key Takeaways from President Trump’s National Call...
Tobacco Head Neck Cancer: Unraveling Mutational Signatures and Prevention Str...
A Shared-Value Model for Enhancing Diabetes Care in South Africa
Oral Cancer in East Africa: The Need for Early Detection